التهاب الجلد التأتبي غير المستجيب للكورتيكوستيرويد الموضعي أو مثبط الكالسينيورين — ما الخطوة التالية

References

DOI: 10.1016/j.anai.2023.11.009

In patients with localized uncontrolled atopic dermatitis refractory to mid-high−potency topical treatment (US classes 2–5 or tacrolimus), the JTF panel suggests addition of a time and body area-limited (eg, 4–7 days; minimum 1 hour to maximum overnight, once per day) trial of occlusive low-mid−potency topical corticosteroid (US classes 3–7) therapy over continued standard topical therapy alone (conditional recommendation, very low-certainty evidence).

Experiential evidence from patients and clinicians suggested that, when used judiciously for specific, local treatment of lesions in a time-limited fashion, most patients experience rapid resolution of AD lesions refractory to corresponding topical treatment without temporary occlusion.